Budesonide/formoterol - MAP Pharmaceuticals

Drug Profile

Budesonide/formoterol - MAP Pharmaceuticals

Alternative Names: MAP 0005

Latest Information Update: 23 Mar 2015

Price : $50

At a glance

  • Originator MAP Pharmaceuticals
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2013 MAP Pharmaceuticals has been acquired by Allergan
  • 25 May 2012 Budesonide/formoterol - MAP Pharmaceuticals is available for partnering in World as of 25 May 2012. http://www.mappharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top